IBRNvsXPH
iShares Neuroscience and Healthcare ETF against SPDR S&P Pharmaceuticals ETF — the fee, the flows, the book, and a year head-to-head.
Head to head
| IBRN | XPH | |
|---|---|---|
| Expense ratio | 0.47% | 0.35% |
| Assets | $6640.17T | $524M |
| Net flow, 1 month | −$60K | −$15M |
| Net flow, 1 year | +$2M | +$274M |
| Return, YTD | +1.7% | +13.9% |
| Return, 1 year | +22.3% | +31.4% |
| Avg daily volume | 2K | 170K |
| Holdings | 54 | 41 |
| Listed | Aug 24, 2022 | Jun 19, 2006 |
| Options market | Yes | Yes |
MARKED CELLS LEAD ON THAT LINE · LOWER FEE, LARGER ASSETS, STRONGER FLOWS & RETURNS